Date Posted:


£1.73million Placing for Scancell Holdings plc

30th June 2011

Zeus Capital has advised Scancell Holdings plc on its £1.73million placing.  Scancell is a biopharmaceutical company focused on the cancer therapeutics market and is developing a series of DNA vaccines for the treatment of cancer based on its patented ImmunoBody® platform, which has the potential to overcome many of the limitations of conventional approaches to the development of cancer vaccines.